First Affirmative Financial Network Buys 1,072 Shares of Sanofi (NASDAQ:SNY)

First Affirmative Financial Network grew its stake in Sanofi (NASDAQ:SNY) by 23.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,598 shares of the company’s stock after acquiring an additional 1,072 shares during the period. First Affirmative Financial Network’s holdings in Sanofi were worth $270,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of SNY. Charles Schwab Investment Management Inc. grew its holdings in Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after acquiring an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors raised its stake in Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after buying an additional 751 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after buying an additional 16,780 shares during the period. JPMorgan Chase & Co. boosted its position in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Finally, GFS Advisors LLC raised its position in shares of Sanofi by 1,017.9% in the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after acquiring an additional 11,655 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Up 3.8 %

Shares of NASDAQ:SNY opened at $54.15 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $137.42 billion, a P/E ratio of 27.63, a P/E/G ratio of 1.21 and a beta of 0.57. The business’s 50-day moving average is $49.12 and its 200 day moving average is $52.24. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. On average, research analysts predict that Sanofi will post 3.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and a consensus price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.